Arnauld Villers

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5410193/arnauld-villers-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

180	15,875	53	125
papers	citations	h-index	g-index
210	19,000 ext. citations	5.9	5.92
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
180	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium <i>European Urology Open</i>	0.9	1
179	Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA) + androgen deprivation therapy (ADT) by high or low disease volume and progression to mHSPC (M0 at diagnosis) or de novo mHSPC (M1 at diagnosis): Post hoc	2.2	O
178	analysis of the phase 3 ARCHES trial. <i>Journal of Clinical Oncology</i> , 2022 , 40, 115-115 Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer <i>Journal of Clinical Oncology</i> , 2022 , JCO2200193	2.2	5
177	Risk Estimation of Metastatic Recurrence After Prostatectomy: A Model Using Preoperative Magnetic Resonance Imaging and Targeted Biopsy. <i>European Urology Open Science</i> , 2022 , 41, 24-34	0.9	O
176	Impact of positive vascular margins status after surgical resection of non-metastatic renal cell carcinoma with caval tumour thrombus: a propensity score multicentre study. <i>World Journal of Urology</i> , 2021 , 1	4	O
175	Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer <i>European Urology Open Science</i> , 2021 , 34, 27-32	0.9	
174	Artificial urinary sphincter implantation in non-neurogenic men: a place for out-patient surgery. <i>World Journal of Urology</i> , 2021 , 39, 3541-3547	4	O
173	Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 781.e17-781.e24	2.8	2
172	Negative Prebiopsy Magnetic Resonance Imaging and Risk of Significant Prostate Cancer: Baseline and Long-Term Followup Results. <i>Journal of Urology</i> , 2021 , 205, 725-731	2.5	8
171	Reply by Authors. <i>Journal of Urology</i> , 2021 , 205, 1371	2.5	
170	The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES <i>Journal of Clinical Oncology</i> , 2021 , 39, 5071-5071	2.2	
169	Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses. <i>Journal of Urology</i> , 2021 , 205, 1361-1371	2.5	3
168	Contribution of serum anti-M l lerian hormone in the management of azoospermia and the prediction of testicular sperm retrieval outcomes: a study of 155 adult men. <i>Basic and Clinical Andrology</i> , 2021 , 31, 15	2.8	3
167	Predictive factors of urinary incontinence after holmium laser enucleation of the prostate: a multicentric evaluation. <i>World Journal of Urology</i> , 2021 , 39, 143-148	4	14
166	Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. <i>BJU International</i> , 2021 , 127, 96-107	5.6	3
165	Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with de novo (M1) metastatic hormone-sensitive prostate cancer (mHSPC) versus progression to mHSPC (M0): Post hoc analysis of the phase III ARCHES trial <i>Journal of Clinical Oncology</i> , 2021 , 39, 102-102	2.2	1
164	Re: Long-term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. <i>European Urology</i> , 2020 , 78, 112	10.2	

163	Impact of age on bladder cancer management practices: a general population study. <i>Acta Oncolgica</i> , 2020 , 59, 462-466	3.2	1
162	Editorial Comment. <i>Journal of Urology</i> , 2020 , 204, 489	2.5	
161	Efficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses <i>Journal of Clinical Oncology</i> , 2020 , 38, 5547-5547	2.2	О
160	Contemporary Techniques of Prostate Dissection for Robot-assisted Prostatectomy. <i>European Urology</i> , 2020 , 78, 583-591	10.2	23
159	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative. <i>European Urology Oncology</i> , 2020 , 3, 80-91	6.7	11
158	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. <i>European Urology</i> , 2019 , 76, 693-702	10.2	12
157	SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2019 , 37, 61-83	4	31
156	Outcomes after salvage radical prostatectomy and first-line radiation therapy or HIFU for recurrent localized prostate cancer: results from a multicenter study. <i>World Journal of Urology</i> , 2019 , 37, 1491-14	9 8	3
155	A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. <i>European Urology</i> , 2019 , 76, 43-51	10.2	163
154	Low-risk prostate cancer selected for active surveillance with negative MRI at entry: can repeat biopsies at 1 year be avoided? A pilot study. <i>World Journal of Urology</i> , 2019 , 37, 253-259	4	8
153	Beyond transrectal ultrasound-guided prostate biopsies: available techniques and approaches. <i>World Journal of Urology</i> , 2019 , 37, 419-427	4	6
152	Surveillance after prostate focal therapy. World Journal of Urology, 2019, 37, 397-407	4	33
151	ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2974-2986	2.2	285
150	Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial <i>Journal of Clinical Oncology</i> , 2019 , 37, 687-687	2.2	18
149	ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC) <i>Journal of Clinical Oncology</i> , 2019 , 37, 5048-5048	2.2	1
148	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. <i>European Urology Oncology</i> , 2019 , 2, 333-336	6.7	4
147	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. <i>European Urology</i> , 2019 , 75, 523-531	10.2	33
146	Prostate cancer heterogeneity: texture analysis score based on multiple magnetic resonance imaging sequences for detection, stratification and selection of lesions at time of biopsy. <i>BJU International</i> 2019 124 76-86	5.6	14

145	Re: Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. <i>European Urology</i> , 2018 , 74, 396	10.2	1
144	MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. <i>New England Journal of Medicine</i> , 2018 , 378, 1767-1777	59.2	1250
143	Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial. <i>Journal of Urology</i> , 2018 , 199, 147-154	2.5	26
142	Editorial Comment. <i>Journal of Urology</i> , 2018 , 200, 1121	2.5	
141	înergence de la simple surveillance du cancer de prostate et des traitements partiels. Rle cl'de llRM Bulletin De LnAcademie Nationale De Medecine, 2018 , 202, 1049-1057	0.1	
140	Surgical Anatomy of the Prostate 2018 , 163-175		
139	The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. <i>Cancer</i> , 2018 , 124, 1197-1206	6.4	41
138	Risk of biochemical recurrence based on extent and location of positive surgical margins after robot-assisted laparoscopic radical prostatectomy. <i>BMC Cancer</i> , 2018 , 18, 1291	4.8	7
137	Multiparametric prostate MRI: technical conduct, standardized report and clinical use. <i>Minerva Urology and Nephrology</i> , 2018 , 70, 9-21	2.3	14
136	TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases. <i>Cancer Letters</i> , 2018 , 438, 32-43	9.9	12
135	Magnetic resonance microscopy may enable distinction between normal histomorphological features and prostate cancer in the resected prostate gland. <i>BJU International</i> , 2017 , 119, 414-423	5.6	4
134	Robot-assisted partial prostatectomy for anterior prostate cancer: a step-by-step guide. <i>BJU International</i> , 2017 , 119, 968-974	5.6	11
133	Quantified analysis of histological components and architectural patterns of gleason grades in apparent diffusion coefficient restricted areas upon diffusion weighted MRI for peripheral or transition zone cancer locations. <i>Journal of Magnetic Resonance Imaging</i> , 2017 , 46, 1786-1796	5.6	11
132	Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure. <i>Nature Reviews Urology</i> , 2017 , 14, 312-322	5.5	37
131	A multicentre randomised controlled trial assessing whether MRI-targeted biopsy is non-inferior to standard transrectal ultrasound guided biopsy for the diagnosis of clinically significant prostate cancer in men without prior biopsy: a study protocol. <i>BMJ Open</i> , 2017 , 7, e017863	3	9
130	Pre-biopsy MRI as an adjunct for cancer detection in men with elevated PSA and no previous biopsy. <i>Translational Andrology and Urology</i> , 2017 , 6, 387-394	2.3	2
129	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. <i>Annals of Internal Medicine</i> , 2017 , 167, 449-455	8	108
128	Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial. <i>European Urology</i> , 2017 , 71, 534-542	10.2	21

127	New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. <i>European Urology</i> , 2017 , 71, 17-34	10.2	165
126	Partial Prostatectomy for Anterior Cancer: Short-term Oncologic and Functional Outcomes. <i>European Urology</i> , 2017 , 72, 333-342	10.2	26
125	Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate Cancer: A Prospective Multicentric Hemiablation Study of 111 Patients. <i>European Urology</i> , 2017 , 71, 267-273	10.2	95
124	Re: Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy. <i>European Urology</i> , 2017 , 71, 301	10.2	1
123	3D Registration of mpMRI for Assessment of Prostate Cancer Focal Therapy. <i>Academic Radiology</i> , 2017 , 24, 1544-1555	4.3	6
122	Focal Therapy for Anterior Cancers (Originated from Transition Zone). <i>Current Clinical Urology</i> , 2017 , 373-382		
121	Pathologic Rationale for Focal Therapy of Prostate Cancer: Elucidating Tumor Characteristics and Biology. <i>Current Clinical Urology</i> , 2017 , 85-104		
120	Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. <i>Lancet Oncology, The</i> , 2016 , 17, 153-163	21.7	164
119	A Critical Analysis of the Current Knowledge of Surgical Anatomy of the Prostate Related to Optimisation of Cancer Control and Preservation of Continence and Erection in Candidates for Radical Prostatectomy: An Update. <i>European Urology</i> , 2016 , 70, 301-11	10.2	149
118	Efficacy and safety of enzalutamide vs bicalutamide in European and North American men participating in the TERRAIN trial <i>Journal of Clinical Oncology</i> , 2016 , 34, 5063-5063	2.2	
117	Robotic-assisted Laparoscopic Bilateral Nerve Sparing and Apex Preserving Cystoprostatectomy in Young Men With Bladder Cancer. <i>Urology</i> , 2016 , 94, 259-64	1.6	6
116	Targeted Anterior Gland Focal Therapy-a Novel Treatment Option for a Better Defined Disease. Current Urology Reports, 2016, 17, 69	2.9	8
	33 1 7 7 7		
115	Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis. <i>Cancer</i> , 2016 , 122, 3386-3393	6.4	14
115 114	Estimating the harms and benefits of prostate cancer screening as used in common practice versus	6.4	14 43
	Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis. <i>Cancer</i> , 2016 , 122, 3386-3393 Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging		,
114	Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis. <i>Cancer</i> , 2016 , 122, 3386-3393 Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies. <i>World Journal of Urology</i> , 2015 , 33, 1669-76 Management of Node Only Recurrence after Primary Local Treatment for Prostate Cancer: A	4	43
114	Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis. <i>Cancer</i> , 2016 , 122, 3386-3393 Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies. <i>World Journal of Urology</i> , 2015 , 33, 1669-76 Management of Node Only Recurrence after Primary Local Treatment for Prostate Cancer: A Systematic Review of the Literature. <i>Journal of Urology</i> , 2015 , 194, 983-8 Image Guided Focal Therapy for Magnetic Resonance Imaging Visible Prostate Cancer: Defining a 3-Dimensional Treatment Margin Based on Magnetic Resonance Imaging Histology Co-Registration	2.5	43

109	Salvage ablative therapy in prostate cancer: international multidisciplinary consensus on trial design. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 495.e1-7	2.8	11
108	The use of partial nephrectomy: results from a contemporary national prospective multicenter study. <i>World Journal of Urology</i> , 2015 , 33, 33-40	4	18
107	Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy. <i>BJU International</i> , 2015 , 116, 888-96	5.6	65
106	How are we going to train a generation of radiologists (and urologists) to read prostate MRI?. <i>Current Opinion in Urology</i> , 2015 , 25, 522-35	2.8	25
105	Understanding the pathological implications of MRI: application to focal therapy planning. <i>Current Opinion in Urology</i> , 2015 , 25, 198-204	2.8	7
104	Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. <i>European Urology</i> , 2015 , 67, 627-36	10.2	234
103	Focal therapy: patients, interventions, and outcomesa report from a consensus meeting. <i>European Urology</i> , 2015 , 67, 771-7	10.2	163
102	Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. <i>European Urology</i> , 2015 , 68, 1045-53	10.2	537
101	Failure or Recurrence Management 2015 , 209-214		
100	TERRAIN Journal of Clinical Oncology, 2015 , 33, 5049-5049	2.2	
100	TERRAIN Journal of Clinical Oncology, 2015, 33, 5049-5049 MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/Etatenin pathway and interaction with SNAIL promoter. Cancer Letters, 2014, 346, 225-36	2.2 9.9	64
	MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/Etatenin pathway		64
99	MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/Etatenin pathway and interaction with SNAIL promoter. <i>Cancer Letters</i> , 2014 , 346, 225-36 Target ablationimage-guided therapy in prostate cancer. <i>Urologic Oncology: Seminars and Original</i>	9.9	·
99 98	MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/Etatenin pathway and interaction with SNAIL promoter. <i>Cancer Letters</i> , 2014 , 346, 225-36 Target ablationimage-guided therapy in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 912-23 Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate	9.9	38 98
99 98 97	MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/Etatenin pathway and interaction with SNAIL promoter. <i>Cancer Letters</i> , 2014 , 346, 225-36 Target ablationimage-guided therapy in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 912-23 Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review. <i>European Urology</i> , 2014 , 65, 1023-31 A novel robotic system for single-port urologic surgery: first clinical investigation. <i>European Urology</i>	9.9 2.8 10.2	38 98 150
99 98 97 96	MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/Etatenin pathway and interaction with SNAIL promoter. <i>Cancer Letters</i> , 2014 , 346, 225-36 Target ablationimage-guided therapy in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 912-23 Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review. <i>European Urology</i> , 2014 , 65, 1023-31 A novel robotic system for single-port urologic surgery: first clinical investigation. <i>European Urology</i> , 2014 , 66, 1033-43 Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in	9.9 2.8 10.2	38 98 150
99 98 97 96	MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/Etatenin pathway and interaction with SNAIL promoter. <i>Cancer Letters</i> , 2014 , 346, 225-36 Target ablationimage-guided therapy in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 912-23 Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review. <i>European Urology</i> , 2014 , 65, 1023-31 A novel robotic system for single-port urologic surgery: first clinical investigation. <i>European Urology</i> , 2014 , 66, 1033-43 Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer. <i>European Urology</i> , 2014 , 66, 655-63 Screening and prostate cancer mortality: results of the European Randomised Study of Screening	9.9 2.8 10.2 10.2	38 98 150

(2013-2014)

91	A different method of evaluation of the ERSPC trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality. <i>European Urology</i> , 2014 , 66, 401-3	10.2	11
90	Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project. <i>BJU International</i> , 2014 , 114, 698-707	5.6	38
89	Multiparametric MRI-targeted TRUS prostate biopsies using visual registration. <i>BioMed Research International</i> , 2014 , 2014, 819360	3	28
88	Modernizing the diagnostic and decision-making pathway for prostate cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 6254-7	12.9	16
87	Microarray gene expression profiling and analysis of bladder cancer supports the sub-classification of T1 tumours into T1a and T1b stages. <i>BJU International</i> , 2014 , 113, 333-42	5.6	15
86	Polytetrafluoroethylene expanded prosthesis as replacement of the inferior vena cava in renal cell carcinoma with caval thrombus. <i>International Journal of Urology</i> , 2014 , 21, 448-52	2.3	6
85	How accurately can MRI detect indolent disease?. Current Opinion in Urology, 2014, 24, 264-9	2.8	5
84	Words of wisdom. Re: Improving detection of clinically significant prostate cancer: MRI/TRUS fusion-guided prostate biopsy. <i>European Urology</i> , 2014 , 65, 1218-9	10.2	4
83	Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. <i>World Journal of Urology</i> , 2014 , 32, 185-91	4	23
82	Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study. <i>World Journal of Urology</i> , 2014 , 32, 1331-8	4	14
81	Role of Imaging as an Adjunct or Replacement for Biopsy: European Experience 2013 , 337-349		
80	ESUR prostate MR guidelines. Author reply. <i>European Radiology</i> , 2013 , 23, 2322-3	8	6
79	Predictive factors of oncologic outcomes in patients who do not achieve undetectable prostate specific antigen after radical prostatectomy. <i>Journal of Urology</i> , 2013 , 190, 1750-6	2.5	33
78	Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 281-4	2.8	25
77	Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. <i>European Urology</i> , 2013 , 63, 125-40	10.2	425
76	Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway?. <i>Journal of Magnetic Resonance Imaging</i> , 2013,	5.6	106
75	Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. <i>European Urology</i> , 2013 , 64, 544-52	10.2	309
74	Surgical Anatomy of the Prostate for Radical Prostatectomy 2013 , 187-198		

73	Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsyprospective multicenter study. <i>Radiology</i> , 2013 , 268, 461-9	20.5	294
7 ²	Pathologic Basis for Focal Therapy: Understanding Cancer Grade, Volume, and Spatial Location 2013 , 53-71		
71	Multimodality MRI-Guided Targeting 2013 , 133-140		
70	Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. <i>BJU International</i> , 2012 , 109, 1636-47	5.6	88
69	Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series. <i>BJU International</i> , 2012 , 110, 517-23	5.6	47
68	A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)-biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy. <i>BJU International</i> , 2012 , 110, 812-20	5.6	72
67	Quality-of-life effects of prostate-specific antigen screening. <i>New England Journal of Medicine</i> , 2012 , 367, 595-605	59.2	279
66	Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. <i>World Journal of Urology</i> , 2012 , 30, 181-7	4	50
65	Prostate-cancer mortality at 11 years of follow-up. New England Journal of Medicine, 2012, 366, 981-90	59.2	875
64	Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. <i>World Journal of Urology</i> , 2012 , 30, 149-55	4	81
63	Focal laser interstitial thermotherapy (LITT) at 980 nm for prostate cancer: treatment feasibility in Dunning R3327-AT2 rat prostate tumour. <i>BJU International</i> , 2012 , 109, 452-8	5.6	28
62	Focal laser ablation of prostate cancer: definition, needs, and future. <i>Advances in Urology</i> , 2012 , 2012, 589160	1.6	33
61	MRI and surveillance. Current Opinion in Urology, 2012, 22, 231-6	2.8	10
60	Assessment of human epidermal growth factor receptor 2 status in urothelial carcinoma of the upper urinary tract: a study using dual-color in situ hybridization and immunohistochemistry. Applied Immunohistochemistry and Molecular Morphology, 2012, 20, 363-6	1.9	10
59	Small cell carcinoma of the upper urinary tract (UUT-SCC): report of a rare entity and systematic review of the literature. <i>Cancer Treatment Reviews</i> , 2011 , 37, 366-72	14.4	31
58	Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification. <i>Urology</i> , 2011 , 78, 607-13	1.6	46
57	Combined multiparametric MRI and targeted biopsies improve anterior prostate cancer detection, staging, and grading. <i>Urology</i> , 2011 , 78, 1356-62	1.6	117
56	Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy. <i>BJU International</i> , 2011 , 108, 1074-85	5.6	75

(2009-2011)

55	Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. <i>BJU International</i> , 2011 , 108, E171-8	5.6	305
54	Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. <i>European Urology</i> , 2011 , 59, 477-94	10.2	537
53	Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. <i>European Urology</i> , 2011 , 60, 366-73	10.2	64
52	Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin. <i>Molecular Cancer Research</i> , 2011 , 9, 914-24	6.6	27
51	Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma. <i>Histopathology</i> , 2010 , 56, 180-7	7.3	86
50	The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. <i>Clinical Cancer Research</i> , 2010 , 16, 4374-81	12.9	72
49	Bases histopathologiques de la thrapie focale dans le cancer localis de la prostate. <i>Progr</i> En <i>Urologie - FMC</i> , 2010 , 20, F96-F100	0	
48	Limited prognostic value of tumor necrosis in patients with renal cell carcinoma. <i>Urology</i> , 2010 , 75, 137	8184	13
47	Multimodality magnetic resonance imaging of prostate cancer. <i>Journal of Endourology</i> , 2010 , 24, 677-86	42.7	27
46	A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. <i>BMC Cancer</i> , 2010 , 10, 635	4.8	64
45	A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy. <i>European Urology</i> , 2010 , 57, 179-92	10.2	328
44	Word of wisdom. Re: three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. <i>European Urology</i> , 2010 , 58, 941-2	10.2	1
43	The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. <i>International Journal of Cancer</i> , 2010 , 126, 2387-93	7·5	49
42	Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). <i>European Urology</i> , 2009 , 56, 584-91	10.2	146
41	Computer-assisted diagnosis of prostate cancer using DCE-MRI data: design, implementation and preliminary results. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2009 , 4, 1-10	3.9	63
40	Transition zone and anterior stromal prostate cancers: zone of origin and intraprostatic patterns of spread at histopathology. <i>Prostate</i> , 2009 , 69, 105-13	4.2	84
39	Peripheral zone prostate cancers: location and intraprostatic patterns of spread at histopathology. <i>Prostate</i> , 2009 , 69, 276-82	4.2	63
38	Race affects access to nephrectomy but not survival in renal cell carcinoma. <i>BJU International</i> , 2009 , 103, 889-93	5.6	21

37	A population-based comparison of survival after nephrectomy vs nonsurgical management for small renal masses. <i>BJU International</i> , 2009 , 103, 899-904; discussion 904	5.6	32
36	Cancer-specific and non-cancer-related mortality rates in European patients with T1a and T1b renal cell carcinoma. <i>BJU International</i> , 2009 , 103, 894-8	5.6	40
35	Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. <i>BJU International</i> , 2009 , 104, 1436-40	5.6	178
34	Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings. <i>European Radiology</i> , 2009 , 19, 470-80	8	130
33	Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. <i>Urology</i> , 2009 , 74, 1094-9	1.6	190
32	Screening and prostate-cancer mortality in a randomized European study. <i>New England Journal of Medicine</i> , 2009 , 360, 1320-8	59.2	2828
31	Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance. <i>Current Opinion in Urology</i> , 2009 , 19, 274-82	2.8	83
30	Imaging of organ-confined prostate cancer: functional ultrasound, MRI and PET/computed tomography. <i>Current Opinion in Urology</i> , 2009 , 19, 168-76	2.8	43
29	The efficacy of intrathecal morphine with or without clonidine for postoperative analgesia after radical prostatectomy. <i>Anesthesia and Analgesia</i> , 2009 , 108, 1954-7	3.9	32
28	Results of endoluminal occlusion of the inferior vena cava during radical nephrectomy and thrombectomy. <i>European Urology</i> , 2008 , 54, 778-83	10.2	13
27	pidmiologie du cancer de la prostate. <i>Medecine Nucleaire</i> , 2008 , 32, 2-4	0.1	8
26	Renal vein ostium wall invasion of renal cell carcinoma with an inferior vena cava tumor thrombus: prediction by renal and vena caval vein diameters and prognostic significance. <i>Journal of Urology</i> , 2008 , 179, 450-4; discussion 454	2.5	49
25	Celiac axis and superior mesenteric artery: danger zone for left nephrectomy. <i>Journal of Endourology</i> , 2008 , 22, 2571-4	2.7	16
24	QuEst-ce que le cancer de la prostate. <i>Bulletin De Ln</i> Academie Nationale De Medecine, 2008 , 192, 1003-10	042	
23	Seasonality of serum prostate-specific antigen levels: a population-based study. <i>European Urology</i> , 2007 , 52, 708-14	10.2	12
22	Prostate cancer computer-assisted diagnosis software using dynamic contrast-enhanced MRI. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2007, 2007, 556	7-70	9
21	Dynamic Contrast-Enhanced MRI for Preoperative Identification of Localised Prostate Cancer. <i>European Urology Supplements</i> , 2007 , 6, 525-532	0.9	20
20	Renal cell carcinoma with rhabdoid features: an aggressive neoplasm with overexpression of p53. <i>Archives of Pathology and Laboratory Medicine</i> , 2007 , 131, 102-6	5	55

(1989-2006)

19	External validation of outcome prediction model for ureteral/renal calculi. <i>Journal of Urology</i> , 2006 , 175, 575-9	2.5	18
18	Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. <i>Journal of Urology</i> , 2006 , 176, 2432-7	2.5	323
17	Endoluminal occlusion of the inferior vena cava in renal cell carcinoma with retro- or suprahepatic caval thrombus. <i>BJU International</i> , 2006 , 97, 1216-20	5.6	35
16	Testicular natural killer T-cell lymphoma. <i>International Journal of Urology</i> , 2005 , 12, 223-4	2.3	19
15	Renal cell carcinoma associated with tumor thrombus in the inferior vena cava: surgical strategies. <i>Annals of Vascular Surgery</i> , 2005 , 19, 522-8	1.7	32
14	What are the survival outcomes for prostate cancer in a population-based cohort of unscreened men?. <i>Nature Reviews Urology</i> , 2005 , 2, 592-3		
13	MUC6 is a marker of seminal vesicle-ejaculatory duct epithelium and is useful for the differential diagnosis with prostate adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2003 , 27, 519-21	6.7	34
12	Modified extrafascial radical retropubic prostatectomy technique decreases frequency of positive surgical margins in T2 cancers . <i>European Urology</i> , 2000 , 38, 64-73	10.2	34
11	Role of preoperative positive apical biopsies in the prediction of specimen-confined prostate cancer after radical retropubic prostatectomy: a multi-institutional study. <i>European Urology</i> , 2000 , 37, 281-8	10.2	13
10	Bladder cancer arising in a spina bifida patient. <i>Urology</i> , 1999 , 54, 923	1.6	8
9	Extraperitoneal endosurgical lymphadenectomy with insufflation in the staging of bladder and prostate cancer. <i>Journal of Endourology</i> , 1993 , 7, 229-35	2.7	14
8	Invasion of Denonvilliers' fascia in radical prostatectomy specimens. <i>Journal of Urology</i> , 1993 , 149, 793-	82.5	102
7	Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. <i>Cancer</i> , 1992 , 70, 2313-8	6.4	199
6	Mucinous differentiation in prostatic adenocarcinoma. <i>Human Pathology</i> , 1991 , 22, 979-88	3.7	46
5	Microcarcinoma in the prostate: its association with duct-acinar dysplasia. <i>Human Pathology</i> , 1991 , 22, 644-52	3.7	101
4	Ultrasound anatomy of the prostate: the normal gland and anatomical variations. <i>Journal of Urology</i> , 1990 , 143, 732-8	2.5	44
3	Transrectal Ultrasound Appearance of Transitional Cell Carcinoma Involving the Prostate. <i>Journal of Urology</i> , 1990 , 143, 953-956	2.5	13
	The role of perineural space invasion in the local spread of prostatic adenocarcinoma. <i>Journal of</i>		278

Localization of Cancer within the Prostate: Dynamic Contrast-Enhanced MRI55-65